SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 134 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $20,248,000 | -20.6% | 1,165,000 | 0.0% | 0.32% | -2.8% |
| Q4 2021 | $25,502,000 | +14.5% | 1,165,000 | 0.0% | 0.33% | +10.9% |
| Q3 2021 | $22,263,000 | +84.6% | 1,165,000 | +65.9% | 0.29% | +81.5% |
| Q2 2021 | $12,059,000 | -73.3% | 702,348 | -65.2% | 0.16% | -75.7% |
| Q1 2021 | $45,100,000 | +4.2% | 2,016,993 | +3.6% | 0.67% | +0.6% |
| Q4 2020 | $43,279,000 | +319.4% | 1,946,000 | +178.3% | 0.66% | +228.7% |
| Q3 2020 | $10,320,000 | +41.4% | 699,200 | +42.0% | 0.20% | +27.0% |
| Q2 2020 | $7,299,000 | +193.5% | 492,500 | +117.3% | 0.16% | +96.3% |
| Q1 2020 | $2,487,000 | -5.5% | 226,680 | +0.7% | 0.08% | -45.6% |
| Q3 2017 | $2,633,000 | -16.2% | 225,000 | 0.0% | 0.15% | -24.0% |
| Q2 2017 | $3,143,000 | – | 225,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |